title: [Phase I study of concurrent radiotherapy with S-1 for oral squamous cell carcinoma].
abstract: S-1 is a novel oral fluoropyrimidine inhibitory for dihydropyrimidine dehydrogenase (DPD). In the present study, we have examined the appropriate dose of S-1 in the combination with radiation and the safety and clinical efficacy. Radiation was given (2 Gy/day; 5 days/week) for a total of 60 Gy. S-1 was given orally every day for 2 weeks and then S-1 was stopped for 1 week. The levels were divided accordingly to the S-1 application as follows; level 0, 50 mg/m2/day; level 1, 65 mg/m2/day; level 2, 80 mg/m2/day. grade 3 toxicity of anorexia and the grade 3 toxicity increase in bilirubin level were observed in 2 cases of level 2. We decided that level 1 (65 mg/m2/day) was the recommended dose of the S-1 application as observed in compliance and efficacy. This therapy is a useful concurrent chemo-radiotherapy which may improve the response rate and quality of life (QOL) of patients with oral squamous cell carcinoma.
authors.affiliation: Dept. of Therapeutic Regulation for Oral Tumors, Graduate School of Health and Bioscience, Tokushima University, Japan.
authors.forename: Mitsunobu
authors.initials: M
authors.lastname: Sato
authors.forename: Koji
authors.initials: K
authors.lastname: Harada
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009325:Nausea / Q000209:etiology; D010094:Oxonic Acid / Q000008:administration & dosage*; D011788:Quality of Life; D011879:Radiotherapy Dosage; D013280:Stomatitis / Q000209:etiology; D005641:Tegafur / Q000008:administration & dosage*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid